Maryland examines GLP-1 drugs beyond weight loss
Three University of Maryland School of Medicine experts examined the potential uses, safety and affordability of GLP-1 medicines in an online discussion on 6 October 2026. The Virtual Face to Face programme was hosted by Bruce E. Jarrell, president of the University of Maryland, Baltimore, according to the university’s account.
The discussion addressed a question increasingly relevant to patients: whether medicines used for diabetes and weight management could eventually help treat a much wider range of conditions. The university highlighted investigations involving joint disease, vascular disease, addiction and neurological disorders, while also setting out concerns about side effects and access.
This was an expert discussion rather than the announcement of a new clinical trial. The university’s accompanying article describes an expanding field of research, but does not provide detailed results establishing effectiveness for each proposed use.
That distinction matters when reading about the potential benefits of GLP-1 drugs beyond weight loss. A possible treatment effect is not the same as evidence that a medicine should routinely be prescribed for a particular condition.
How GLP-1 medicines work and why research is widening
GLP-1 is a naturally occurring gut hormone. Medicines known as GLP-1 receptor agonists mimic its activity, helping the pancreas release insulin when blood glucose rises and reducing the release of glucagon, which raises blood glucose. They also slow stomach emptying and help people feel full for longer.
The medicines were initially developed to treat type 2 diabetes. Their use in weight management reflects the effect they can have on appetite and food intake, rather than a requirement for people to demonstrate greater willpower.
The university places the research in the context of the health conditions associated with obesity. These include high blood pressure, heart disease, stroke, obstructive sleep apnoea, fatty liver disease and certain cancers. Its account estimates that about 40 per cent of American adults have obesity.
Among the possible additional applications it lists are osteoarthritis, peripheral artery disease, atherosclerosis, endometriosis and addiction, as well as Alzheimer’s and Parkinson’s diseases. The article does not establish which benefits might arise through weight reduction and which might involve other effects of the medicines.
It also refers to research published in Nature reporting signs of slower ageing in mice. Findings in animals cannot establish that the same treatment slows human ageing, and the university’s account provides no human longevity results.
The development history offers another distinction between the hormone and the medicines. Jean-Pierre Raufman, one of the programme’s guests, worked with colleagues studying Gila monster venom. They investigated exendin-4, a peptide that activates the GLP-1 receptor and lasts much longer in the body than natural human GLP-1, helping lay the groundwork for subsequent treatments.
Maryland specialists bring clinical and research perspectives
Jarrell’s guests included Rozalina McCoy, an associate professor and vice chief of clinical research in the medical school’s Division of Endocrinology, Diabetes, and Nutrition. Kashif Munir, a professor of medicine in the same division, brought experience treating diabetes, thyroid conditions and pituitary disorders.
Raufman, who chairs the school’s Division of Gastroenterology and Hepatology, provided a connection to the early research behind the drug class. The university’s written account identifies the participants and their expertise but does not reproduce their individual answers, so it does not support attributing specific recommendations to them.
In its overview, the university identifies nausea and acid reflux as common side effects. It also notes that rapid weight reduction can include loss of muscle as well as fat, an issue explored in our coverage of GLP-1 treatment and muscle loss.
The account raises concerns about thyroid cancer and a rare condition involving acute vision loss, while describing serious adverse effects as uncommon. It supplies no risk estimates or evidence establishing causation for those concerns; they should not be read as equivalent, proven risks across every medicine in the class.
GLP-1 evidence and access remain open questions
For the proposed new uses, the university’s report gives no timetable for regulatory decisions or routine treatment. It also leaves unanswered which medicines, doses and patient groups might benefit. Research involving one treatment or condition cannot settle those questions for the entire drug class.
Affordability is a separate obstacle. The university reports that many US insurers restrict coverage for weight management alone, while coverage for type 2 diabetes is more commonly approved. It puts Ozempic’s US list price at almost $1,000 a month and says manufacturer discounts can still leave costs of several hundred dollars.
Those are American pricing and insurance arrangements, not an account of NHS availability. For UK readers, the Maryland discussion is principally a view of the developing science: it announces neither a change in NHS access nor a new UK treatment indication.
